Table 1 Baseline clinical characteristics.

From: The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence

N = 21

 

Age (years), median (IQR)

61 (57–69.25)

Male

18 (85.7%)

Smoking status

 Never

6 (28.6%)

 Yes

(current/past)

15 (71.4%)

(13/2)

Thoracic radiotherapy

 Yes

9 (42.9%)

 No

12 (57.1%)

PD-1 inhibitor

16 (76.2%)

PD-L1 inhibitor

5 (23.8%)

Treatment line

 1

17 (81.0%)

≧2

4 (19.0%)

Bronchoscopy results

BALF

Lymphocyte percentage (N = 19*)

≧20%

14 (73.7%)

 < 20%

5 (26.3%)

CD4/CD8 ratio (N = 15#)

≧1

6 (37.5%)

 < 1

9 (62.5%)

Pathology (N = 13)

 OP

5 (38.4%)

 AFOP

3 (23.1%)

 NSIP

3 (23.1%)

 DAD

2 (15.4%)

  1. *Of the 21 patients who underwent bronchoscopy, BALF differential cell count was performed in 19 patients.
  2. #Lymphocyte subset testing was performed in 15 patients.
Back to article page